STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
Extina (ketoconazole) Foam, 2% was approved for marketing in the United States (US) in June
2007. Extina foam is indicated for topical treatment of seborrheic dermatitis in
immunocompetent patients 12 years of age and older. The approved dosing regimen is twice
daily for 4 weeks. The treatment of recurrent seborrheic dermatitis demands a topical
preparation that is safe for both short-term and chronic application. This study is being
conducted in order to obtain long-term safety data on the use of Extina (ketoconazole) Foam,
2% in the treatment of seborrheic dermatitis.